Patents Assigned to Merck
  • Publication number: 20190270932
    Abstract: The present invention relates to a light luminescent particle comprising a nanosized light emitting material, and use of said light luminescent particle. The present invention further relates to a composition comprising a light luminescent particle, an optical medium, and an optical device. The present invention also relates to method for preparing of said luminescent particle.
    Type: Application
    Filed: November 8, 2017
    Publication date: September 5, 2019
    Applicant: Merck Patent GmbH
    Inventor: Arjan MEIJER
  • Publication number: 20190270745
    Abstract: The invention is directed towards stable formulations of 5,10-methylene-(6R)-tetrahydrofolic acid and its hemisulfate salt as well as pharmaceutical compositions and uses thereof in therapy, preferably chemotherapy.
    Type: Application
    Filed: May 17, 2019
    Publication date: September 5, 2019
    Applicant: MERCK & CIE
    Inventors: Rudolf MOSER, Viola GROEHN, Thomas EGGER, Thomas AMMANN
  • Patent number: 10400040
    Abstract: Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Xiao Min Schebye, Grigori P. Ermakov, Douglas J. Hodges, Leonard G. Presta
  • Patent number: 10400169
    Abstract: The invention relates to a liquid-crystalline medium which comprises at least one compound of the formula I, in which R1, R1*, Z1, Z2 and L1-3 have the meanings defined herein, and to the use thereof for an active-matrix display, in particular based on the VA, PSA, PS-VA, PALC, FFS, PS-FFS, PS-IPS or IPS effect.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 3, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Harald Hirschmann, Monika Bauer, Martina Windhorst, Marcus Reuter, Constanze Brocke, Rocco Fortte, Matthias Bremer, Sabine Schoen
  • Patent number: 10399957
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TLR7/8 antagonists.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: September 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Brian A. Sherer, Nadia Brugger
  • Patent number: 10403833
    Abstract: The present invention relates inter alia to novel organic metal complexes comprising, e.g., platinum and specific side groups, their preparation und their use in electronic devices.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: September 3, 2019
    Assignee: Merck Patent GmbH
    Inventors: Rèmi Manouk Anémian, Noriyuki Matsuda
  • Patent number: 10399972
    Abstract: The present invention is directed to tricyclic compounds of formula (I), (Ia) or (Ib) which are inhibitors of one or more mutant IDH enzymes. The present invention is also directed to uses of these tricyclic compounds in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: September 3, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David J. Witter, Tesfaye Biftu, Purakkattle Biju, Stephane L. Bogen, Qingmei Hong, Chunhui Huang, Xianhai Huang, Bing Li, Min K. Park, David L. Sloman
  • Patent number: 10401322
    Abstract: A separation unit is a configuration that is arranged vertically, and thus bubbles generating from the electrode will not negatively influence the contact location between the transfer membrane and separation unit. An anode (32) is arranged at a position separated by a certain distance in the conveying direction (X) of the transfer membrane (1) from the dispensing part (50a) of an electrophoresis gel chip (50). An insulating electrode cover (35) for setting free bubbles generating from the anode (32) is arranged at an upper part of the anode (32).
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: September 3, 2019
    Assignee: Merck LTD.
    Inventors: Taiga Tominaga, Hideki Kinoshita, Shinichi Goto, Mieko Hirabayashi, Kouhei Kageyama, Takateru Matsunaga, Kimihiko Yabe
  • Publication number: 20190263831
    Abstract: Provided herein is a method for the synthesis of cephalosporin antibiotic compounds comprising a palladium-catalyzed coupling reaction.
    Type: Application
    Filed: November 6, 2018
    Publication date: August 29, 2019
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: David Waller, Gregory Gazda, Zachary Minden, Lisa Barton, Clifton Leigh
  • Publication number: 20190265219
    Abstract: The invention relates to a method for determining ammonium or ammonia in aqueous samples in accordance with the known Berthelot method, wherein the risk of incorrectly low results is greatly reduced by additionally measuring the extinction in the absorption range of the nitroprusside used as a catalyst.
    Type: Application
    Filed: September 18, 2017
    Publication date: August 29, 2019
    Applicant: MERCK PATENT GMBH
    Inventor: Ralf OLT
  • Publication number: 20190262365
    Abstract: Compounds of Formula (I): (Formula (I)) and their pharmaceutically acceptable salts are useful for the inhibition of HIV reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antiviral agents, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: October 20, 2017
    Publication date: August 29, 2019
    Applicants: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC.
    Inventors: Jean-Laurent Paparin, Houcine Rahali, Aurélien Salanson, Daniel Da Costa, David Dukhan, Timothy J. Hartingh, Izzat Raheem, John Schreier
  • Publication number: 20190264105
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays comprising it.
    Type: Application
    Filed: October 16, 2017
    Publication date: August 29, 2019
    Applicant: MERCK PATENT GMBH
    Inventors: Nils GREINERT, Matthias BREMER, Patrick SUESS, Christian SCHOENEFELD, Jochen SIEBERLING, Renate SEEGER, Anna Lisa HAWLITSCHEK
  • Publication number: 20190263927
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of urothelial cancer.
    Type: Application
    Filed: October 13, 2017
    Publication date: August 29, 2019
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventor: Martin S. OLIVO
  • Patent number: 10392561
    Abstract: The invention relates to bimesogenic compounds of formula I wherein R11, R12, MG11, MG12, X11, X12 and Sp1 have the meaning given in claim 1, to the use of bimesogenic compounds of formula I in liquid crystal media and particular to flexoelectric liquid crystal devices comprising a liquid crystal medium according to the present invention.
    Type: Grant
    Filed: December 8, 2015
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Detlef Pauluth, Kevin Adlem, Owain Llyr Parri, Rachel Tuffin, Hassan Arasi, Patricia Eileen Saxton
  • Patent number: 10392332
    Abstract: The present invention relates to novel compounds containing fluorinated end groups, to the use thereof as surface-active substances, and to compositions comprising these compounds.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: August 27, 2019
    Assignee: MERCK PATENT GmbH
    Inventors: Reiner Friedrich, Gerhard Jonschker
  • Patent number: 10396297
    Abstract: The present application relates to a material comprising a monoarylamine of a defined formula and a p-dopant of a defined formula. The present application further relates to the use of said material in an organic layer of an electronic device, the device preferably being an organic electroluminescent device (OLED).
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Frank Voges, Frank Stieber, Philipp Stoessel, Teresa Mujica-Fernaud, Christof Pflumm, Joachim Kaiser
  • Patent number: 10391418
    Abstract: The present invention relates to a process for the vacuum purification of chemical compounds and to an apparatus for carrying out this process.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stossel, Juergen Fuchs
  • Patent number: 10392375
    Abstract: The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: August 27, 2019
    Assignee: Merck Patent GmbH
    Inventors: Catherine Jorand-Lebrun, Ruoxi Lan, Austin Chen, Ryan C. Clark
  • Patent number: 10392353
    Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 27, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Guy R. Humphrey, Zhijian Liu, Mark McLaughlin, Yingju Xu, Younong Yu
  • Publication number: 20190256771
    Abstract: The present invention relates to liquid-crystalline media (LC media) having negative or positive dielectric anisotropy comprising self-aligning mesogens (SAMs) which effect homeotropic (vertical) alignment of the LC media at a surface or the cell walls of a liquid-crystal display (LC display). The invention therefore also encompasses LC displays having homeotropic alignment of the liquid-crystalline medium (LC medium) without conventional imide alignment layers. The LC media may be supplemented by a polymerisable or polymerised component, which serves for stabilisation of the alignment, for adjustment of the tilt angle and/or as passivation layer.
    Type: Application
    Filed: April 29, 2019
    Publication date: August 22, 2019
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Archetti GRAZIANO, Andreas TAUGERBECK